Table 3

Prediction of response: odds ratios (OR) and 95% confidence intervals (CI) of BASDAI 50 response; results are shown for univariate (total population and for each drug separately) and multivariate (total population only) logistic regression analysis

Univariate analysis OR (95%CI)Multivariate analysis (best model) OR (95%CI)
Total population (n = 99)p ValueInfliximab (n = 69)p ValueEtanercept (n = 30)p ValueTotal group (n = 99)
*OR refers to the risk of achieving a BASDAI 50 response per year of disease duration/age; †OR refers to the risk per one grade on a 0–10 scale; ‡OR refers to the risk if HLA-B27 is positive (v negative); §OR refers to the risk per 1 mg/l increase of CRP; ¶OR refers to the risk if peripheral arthritis or enthesitis, respectively, is present (v absent).
Disease duration*0.93 (0.88 to 0.98)0.0030.95 (0.89 to 1.00)0.0500.89 (0.80 to 0.99)0.0150.94 (0.89 to 0.99)
Age*0.94 (0.90 to 0.99)0.0090.94 (0.88 to 0.995)0.0260.95 (0.87 to 1.04)0.24
BASFI†0.75 (0.60 to 0.93)0.0070.81 (0.63 to 1.04)0.0880.47 (0.25 to 0.88)0.0040.54 (0.38 to 0.76)
HLA-B27 positive‡3.22 (0.78 to 13.3)0.0922.94 (0.53 to 16.4)0.194.0 (0.32 to 50.2)0.27
CRP (mg/l)§1.02 (1.001 to 1.04)0.0351.02 (1.00 to 1.04)0.0661.04 (0.99 to 1.09)0.121.02 (1.002 to 1.05)
BASDAI†1.34 (0.96 to 1.87)0.0821.44 (0.97 to 2.12)0.0611.03 (0.52 to 2.03)0.932.26 (1.34 to 3.81)
BASMI†0.88 (0.72 to 1.07)0.200.88 (0.69 to 1.11)0.260.85 (0.56 to 1.29)0.44
Peripheral arthritis¶0.45 (0.20 to 1.02)0.0530.53 (0.20 to 1.41)0.200.30 (0.06 to 1.42)0.12
Enthesitis¶1.02 (0.46 to 2.27)0.961.07 (0.42 to 2.77)0.881.02 (0.22 to 4.78)0.98